The CHMP recommended approval of gefurulimab (Klygefa), a weekly self-administered C5 inhibitor, for AChR-antibody-positive generalized myasthenia gravis in the EU.
|Videos|May 30, 2020
CMSC 2020 Day 3: Mark Freedman, MSc, MD, on Stem Cell Research
Author(s)NeurologyLive® Staff
Mark Freedman, MSc, MD, presents the John F. Kurtzke Lecture, titled "Stem Cell Research Update" as part of the 2020 CMSC Virtual Annual Meeting.
Advertisement
For more coverage from CMSC 2020,
To register for the 2020 CMSC Virtual Annual Meeting, May 26-29, 2020,
To complete the evaluation and claim credit, go to
Advertisement
Related to this article
Here's some of what is coming soon to NeurologyLive® this week.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease biomarkers!
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in glioblastoma beyond extent of resection and sex.
The approval, based on phase 3 IB1001-303 trial data showing consistent SARA scale improvement, makes levacetylleucine the first treatment approved specifically for ataxia-telangiectasia.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 18, 2026.
A published protocol outlines the randomized, open-label EPOCH trial testing whether cilostazol accelerates hematoma resorption and improves recovery after intracerebral hemorrhage.
Brian Lin, PhD, discussed the current evidence linking football participation with ALS, the questions that remain unanswered, and how emerging research may help clarify the association.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Levacetylleucine for Ataxia-Telangiectasia
2
FDA Clears Phase 1b/2 Trial of CAR T-Cell Therapy C-CAR168 for Refractory Progressive Multiple Sclerosis
3
Episode 175: Advancing the Ways of Treating Cluster Headache
4
FDA Approves UX111, First Gene Therapy for Pediatric Sanfilippo Syndrome Type A
5